Skip to main content
Premium Trial:

Request an Annual Quote

Invitae Files $250M Shelf Registration

NEW YORK (GenomeWeb) – Invitae has filed a shelf registration with the US Securities and Exchange Commission, under which it may offer up to $250 million of common and/or preferred stock, debt securities, depositary shares, or warrants.

The company also said that it signed a sales agreement with Cowen and Company allowing for the sale up to $75 million of its common stock.

The $75 million of common stock covered by the agreement with Cowen is included in the $250 million of securities that may sold by the company under the base prospectus. If any portion of the stock under the agreement with Cowen is not sold by the time the agreement terminates, then it may be offered for sale as part of the base prospectus or a supplement prospectus.

Invitae said that it intends to use proceeds from the offering for general corporate purposes.

Earlier this week, the genetic testing firm reported that its second quarter revenues more than doubled year over year on test volume growth and an improved reimbursement landscape.

In Friday morning trade on the New York Stock Exchange, shares of Invitae were down around 1 percent at $9.79.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.